Interleukin-27 Protects Cardiomyocyte-Like H9c2 Cells against Metabolic Syndrome: Role of STAT3 Signaling.

BioMed Research International
Wei-Lian PhanMing-Chieh Ma

Abstract

The present results demonstrated that high glucose (G), salt (S), and cholesterol C (either alone or in combination), as mimicking extracellular changes in metabolic syndrome, damage cardiomyocyte-like H9c2 cells and reduce their viability in a time-dependent manner. However, the effects were greatest when cells were exposed to all three agents (GSC). The mRNA of glycoprotein (gp) 130 and WSX-1, both components of the interleukin (IL)-27 receptor, were present in H9c2 cells. Although mRNA expression was not affected by exogenous treatment with IL-27, the expression of gp130 mRNA (but not that of WSX-1 mRNA) was attenuated by GSC. Treatment of IL-27 to H9c2 cells increased activation of signal transducer and activator of transcription 3 (STAT3) and protected cells from GSC-induced cytochrome c release and cell damage. The protective effects of IL-27 were abrogated by the STAT3 inhibitor, stattic. The results of the present study clearly demonstrate that the STAT3 pathway triggered by anti-inflammatory IL-27 plays a role in protecting cardiomyocytes against GSC-mediated damage.

References

Jun 15, 1997·The Journal of Clinical Investigation·Y FujioT Kishimoto
May 23, 1998·Annual Review of Immunology·W J Leonard, J J O'Shea
Dec 18, 2001·The Journal of Biological Chemistry·Tomoaki OsugiTadamitsu Kishimoto
Aug 27, 2003·Investigative Ophthalmology & Visual Science·Ruben N SanchezTim T Lam
Feb 7, 2004·The Journal of Immunology : Official Journal of the American Association of Immunologists·Stefan PflanzRobert A Kastelein
Mar 17, 2004·Journal of Cell Science·Jason S RawlingsDouglas A Harrison
Jul 9, 2004·The Journal of Immunology : Official Journal of the American Association of Immunologists·Alejandro V VillarinoChristopher A Hunter
May 25, 2005·Archives of Internal Medicine·Marianne ZellerUNKNOWN Observatoire des Infarctus de Côte-d'Or Survey Working Group
Jul 19, 2005·Journal of the American College of Cardiology·Giacomo LevantesiUNKNOWN GISSI-Prevenzione Investigators
Aug 2, 2005·Laboratory Investigation; a Journal of Technical Methods and Pathology·Kenichi MatsushitaSatoshi Ogawa
Mar 7, 2006·American Journal of Physiology. Heart and Circulatory Physiology·Eric R GrossGarrett J Gross
Dec 15, 2006·Nature·Luc F Van GaalChristophe E De Block
Aug 28, 2007·Journal of the American College of Cardiology·Najmeddine EchahidiPatrick Mathieu
Nov 6, 2007·American Journal of Physiology. Heart and Circulatory Physiology·Lynn C HuffmanKaryn L Butler
Mar 14, 2008·Journal of Thrombosis and Thrombolysis·Francesca MarzoFelicita Andreotti
Jan 10, 2009·Science·Joanna WegrzynAndrew C Larner
Jan 24, 2009·Immunological Reviews·Hiroki YoshidaMiyazaki Yoshiyuki
Jul 27, 2010·American Journal of Physiology. Heart and Circulatory Physiology·Christopher C T SmithDerek M Yellon
Aug 14, 2010·Mediators of Inflammation·Rosário Monteiro, Isabel Azevedo
Apr 24, 2012·Journal of Nutrition and Metabolism·Faloia EmanuelaBoscaro Marco
Apr 1, 2012·JAK-STAT·Richard A KnightAnastasis Stephanou
Nov 8, 2013·BioMed Research International·Mohammad Zahid KamranRajiv P Gude
Apr 1, 2014·Biochemical and Biophysical Research Communications·Aibin XuLing Tao

❮ Previous
Next ❯

Methods Mentioned

BETA
coronary artery bypass
enzyme-linked immunosorbent assay
PCR
ELISA
transgenic

Related Concepts

Related Feeds

Anti-inflammatory Treatments

A drug or substance that reduces inflammation (redness, swelling, and pain) in the body. Anti-inflammatory agents block certain substances in the body that cause inflammation and swelling. Discover the latest research on anti-inflammatory treatments here